Skip to main content
MTVA
NASDAQ Life Sciences

MetaVia Adds Uric Acid Win to DA-1726 Liver Data, Targets Phase 2 in H2 2027

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$1.51
Mkt Cap
$9.487M
52W Low
$0.966
52W High
$13.42
52W Position info
56% above low
Off High info
89% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

MTVA sits 56% above its 52-week low of $0.966.

Summary

MetaVia reported a new statistically significant uric acid reduction (1.47 mg/dL placebo-adjusted, p<0.001) from the same Phase 1 Part 3B trial that previously showed 68.1% liver fat and 13.5% weight loss. Full data lands in Q1 2027, ahead of a planned Phase 2 in H2 2027.


Key Events · Product Development and Regulatory · MTVA

  • New Uric Acid Endpoint Hits Significance

    At Day 109, DA-1726 cut serum uric acid by 1.02 mg/dL from a 5.89 mg/dL baseline, versus a 0.45 mg/dL increase on placebo — a 1.47 mg/dL placebo-adjusted reduction (p<0.001), despite normal baseline levels.

  • Liver Fat Normalized in Steatosis Subjects

    By Day 109, all five DA-1726-treated participants with baseline steatosis reached MRI-PDFF below 5%, adding to the previously reported 68.1% placebo-adjusted liver fat reduction.

  • Small Sample Limits Read-Through

    The interim analysis covers 15 DA-1726-treated and four placebo participants, with an MRI substudy of 12 treated and four placebo — supportive but not definitive.

  • Full Data and Phase 2 Timeline

    Full Part 3A and Part 3B data are expected in Q1 2027; a 48-week, non-biopsy Phase 2 in up to 150 MetALD/ALD subjects is targeted to begin in H2 2027.


Analysis · MTVA · Life Sciences

What matters here is that the November 5 readout of 68.1% liver fat reduction and 13.5% weight loss now carries a new statistically significant endpoint: a 1.47 mg/dL placebo-adjusted uric acid reduction (p<0.001) after 16 weeks, achieved even though participants started with normal mean uric acid levels. All five DA-1726-treated subjects with baseline steatosis cleared below the 5% MRI-PDFF threshold — the kind of clean liver signal that supports the MetALD/ALD positioning the company is selling. The trial is tiny, with 15 treated versus four placebo, so this is supportive rather than definitive. The real value test comes with full Part 3A/3B data in Q1 2027 and a 48-week Phase 2 in up to 150 subjects targeted for the second half of 2027. For a company this small, a broadening efficacy profile ahead of a capital-hungry Phase 2 is the difference between raising on strength and raising on desperation.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MTVA was trading at $1.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.5M. The 52-week trading range was $0.97 to $13.42. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MTVA - Latest Insights

MTVA
Nov 05, 2026, 9:15 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.32
Real-time Price: $1.37 info
Change: +$0.0507 (+4%) info
Market Cap: $8.565M info
MTVA
Aug 06, 2026, 4:05 PM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $1.45
Real-time Price: $1.37 info
Change: -$0.080 (-6%) info
Market Cap: $8.565M info
MTVA
Jul 09, 2026, 8:35 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.59
Real-time Price: $1.37 info
Change: -$0.2185 (-14%) info
Market Cap: $8.565M info
MTVA
Jul 02, 2026, 4:13 PM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $1.42
Real-time Price: $1.37 info
Change: -$0.050 (-4%) info
Market Cap: $8.565M info
MTVA
Jul 02, 2026, 4:05 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $1.48
Real-time Price: $1.37 info
Change: -$0.110 (-7%) info
Market Cap: $8.565M info